Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$1.39 -3.8%	$1.70	$1.39 ▼ $3.63	$54.09M	0.31	34,615 shs	32,234 shs
ENGN enGene	$4.48 +4.2%	$5.96	$4.20 ▼ $17.54	$228.38M	-0.61	130,589 shs	3,570 shs
FHTX Foghorn Therapeutics	$3.65 +3.7%	$4.62	$3.38 ▼ $10.25	$202.98M	3.13	134,193 shs	341,292 shs
YMAB Y-mAbs Therapeutics	$4.43 -7.9%	$5.58	$4.25 ▼ $17.78	$200.32M	0.65	334,040 shs	392,180 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	-10.00%	-14.79%	-11.11%	-59.66%
ENGN enGene	0.00%	-13.31%	-28.45%	-36.30%	-74.63%
FHTX Foghorn Therapeutics	0.00%	-13.09%	-27.42%	-23.64%	-47.54%
YMAB Y-mAbs Therapeutics	0.00%	-3.80%	-13.43%	-38.02%	-70.42%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENGN enGene	3.1274 of 5 stars	3.5	5.0	0.0	0.0	1.7	2.5	0.6
FHTX Foghorn Therapeutics	2.5651 of 5 stars	3.5	3.0	0.0	0.0	2.5	1.7	0.6
YMAB Y-mAbs Therapeutics	3.6676 of 5 stars	4.5	3.0	0.0	0.0	1.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	0.00	N/A	N/A	N/A
ENGN enGene	3.00	Buy	$25.22	463.00% Upside
FHTX Foghorn Therapeutics	3.00	Buy	$13.17	260.73% Upside
YMAB Y-mAbs Therapeutics	2.91	Moderate Buy	$18.30	313.09% Upside

Current Analyst Ratings Breakdown

Latest BYSI, ENGN, FHTX, and YMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $12.00
3/11/2025	ENGN enGene	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$37.00 ➝ $34.00
3/11/2025	ENGN enGene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/7/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $18.00
3/5/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
3/5/2025	YMAB Y-mAbs Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$11.00 ➝ $7.00
3/3/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$23.00
2/18/2025	ENGN enGene	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
2/14/2025	ENGN enGene	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$34.00 ➝ $7.00
1/30/2025	FHTX Foghorn Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	$1.88M	28.83	N/A	N/A	($0.91) per share	-1.52
ENGN enGene	N/A	N/A	N/A	N/A	$6.17 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	8.98	N/A	N/A	($1.83) per share	-1.99
YMAB Y-mAbs Therapeutics	$87.69M	2.28	N/A	N/A	$2.32 per share	1.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$21.03M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ENGN enGene	-$55.14M	-$1.52	N/A	N/A	N/A	N/A	-16.69%	-14.27%	N/A
FHTX Foghorn Therapeutics	-$98.43M	-$1.65	N/A	N/A	N/A	-357.53%	N/A	-30.98%	5/5/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.67	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	5/6/2025 (Estimated)

Latest BYSI, ENGN, FHTX, and YMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/6/2025	Q4 2024	FHTX Foghorn Therapeutics	-$0.43	-$0.30	+$0.13	-$0.30	$8.56 million	$2.86 million
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
ENGN enGene	$1.58	35.29%	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	1.82	N/A
ENGN enGene	0.08	16.87	16.87
FHTX Foghorn Therapeutics	N/A	4.77	4.77
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
ENGN enGene	64.16%
FHTX Foghorn Therapeutics	61.55%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
ENGN enGene	13.70%
FHTX Foghorn Therapeutics	9.07%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	80	39.03 million	27.59 million	Optionable
ENGN enGene	31	50.98 million	38.16 million	N/A
FHTX Foghorn Therapeutics	120	55.61 million	50.57 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.22 million	34.71 million	Optionable

BYSI, ENGN, FHTX, and YMAB Headlines

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages

March 26, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of "Moderate Buy" by Brokerages

March 26, 2025 | marketbeat.com

Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views

March 23, 2025 | nasdaq.com

HC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00

March 22, 2025 | marketbeat.com

Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright

March 21, 2025 | markets.businessinsider.com

4YMAB : Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views

March 21, 2025 | benzinga.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Sells $20,368.40 in Stock

March 12, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 10,810 Shares

March 12, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi Sells 3,917 Shares

March 12, 2025 | insidertrades.com

Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates

March 9, 2025 | finance.yahoo.com

YMAB FY2025 EPS Forecast Lowered by Cantor Fitzgerald

March 8, 2025 | marketbeat.com

Q1 EPS Estimate for Y-mAbs Therapeutics Boosted by Analyst

March 8, 2025 | marketbeat.com

Wedbush Equities Analysts Lower Earnings Estimates for YMAB

March 8, 2025 | marketbeat.com

Truist Financial Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $18.00

March 6, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Given New $12.00 Price Target at Bank of America

March 6, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Given New $7.00 Price Target at Morgan Stanley

March 6, 2025 | marketbeat.com

Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics

March 5, 2025 | benzinga.com

Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA

March 5, 2025 | markets.businessinsider.com

Y-Mabs Therapeutics (YMAB) Gets a Buy from Oppenheimer

March 5, 2025 | markets.businessinsider.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call Transcript

March 5, 2025 | msn.com

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript

March 4, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, ENGN, FHTX, and YMAB Company Descriptions

BeyondSpring NASDAQ:BYSI

$1.39 -0.05 (-3.75%)

Closing price 03:58 PM Eastern

Extended Trading

$1.38 0.00 (-0.07%)

As of 04:05 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

enGene NASDAQ:ENGN

$4.48 +0.18 (+4.19%)

Closing price 04:00 PM Eastern

Extended Trading

$4.47 -0.01 (-0.11%)

As of 06:21 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Foghorn Therapeutics NASDAQ:FHTX

$3.65 +0.13 (+3.69%)

Closing price 04:00 PM Eastern

Extended Trading

$3.65 0.00 (0.00%)

As of 06:38 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.43 -0.38 (-7.90%)

Closing price 04:00 PM Eastern

Extended Trading

$4.40 -0.02 (-0.56%)

As of 06:15 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time